Firmagon 80mg (Degarelix Vials) 80mg

Degarelix, the active ingredient in Firmagon, is a GnRH antagonist. It binds to the pituitary GnRH receptors, reducing the release of gonadotropins and consequently lowering testosterone levels. This suppression of testosterone helps to inhibit the growth of prostate cancer cells that are dependent on hormones for their growth.

The dose of Firmagon is determined by a healthcare provider based on the patient's condition and response to treatment. It is typically administered as a subcutaneous injection. The initial dose is usually higher, followed by a maintenance dose. Always follow the prescribed dosage and administration instructions provided by your healthcare provider.

Firmagon is not indicated for use in women, and its safety during pregnancy or breastfeeding has not been established. It is primarily used in the treatment of prostate cancer in men. Pregnant women or those planning to become pregnant should avoid exposure to Firmagon. Consult your healthcare provider for more information.

To order Firmagon from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

Firmagon is a GnRH antagonist, which differs from GnRH agonists like leuprolide or goserelin. Unlike agonists, which initially cause a temporary increase in testosterone levels, antagonists like Degarelix provide an immediate and sustained suppression of testosterone. This can be beneficial for patients who require rapid testosterone reduction.

Firmagon should be stored at 2-8°C, kept refrigerated, and protected from light. It should not be frozen or shaken. Always follow the storage instructions provided with the medication to ensure its effectiveness and safety. Proper handling and storage are crucial to maintain the integrity of the injectable solution.

Firmagon is administered as a subcutaneous injection, typically in the abdominal area. The injection should be performed by a healthcare professional or as directed by a healthcare provider. The initial dose is usually higher, followed by a maintenance dose. Always follow the administration instructions provided by your healthcare provider.

The most serious risks associated with Firmagon include allergic reactions, severe skin reactions, changes in blood pressure, heart rhythm abnormalities, and an increased risk of diabetes or hyperglycemia. Patients should be monitored regularly for these potential side effects, and any adverse reactions should be reported to a healthcare provider immediately.

Firmagon should not be used by individuals who are allergic to Degarelix or any of the excipients in the formulation. It is not indicated for use in women, and its safety in children has not been established. Patients with a history of heart disease, diabetes, or osteoporosis should use Firmagon with caution and under medical supervision.